TNFSF9在原发性胆汁性肝硬化的表达及其临床意义  

Expression of TNFSF9 in primary biliary cirrhosis and its clinical significance

作　　者：王淇泓[1] 周晔[1] 胡志德[1] 王爱华[1] 邓燕[1] 邓安梅[1] 仲人前[1] 

机构地区：[1]解放军第二军医大学长征医院实验诊断科,全军临床免疫中心,上海200003

出　　处：《临床军医杂志》2010年第4期558-559,共2页Clinical Journal of Medical Officers

基　　金：国家自然科学基金项目(30671840;30772017;30770997);上海市科委基金项目(08QH14001)

摘　　要：目的探讨原发性胆汁性肝硬化(PBC)患者血清TNFSF9的浓度变化及其临床意义。方法采用酶联免疫吸附试验(ELISA)检测42例PBC患者及与之配对的健康人血清中TNFSF9水平,并分析PBC患者血清TNFSF9与TBIL、γ-GT的关系。结果 PBC患者血清TNFSF9水平(1102.45±294.48)ng/L比健康对照组(123.67±62.60)ng/L显著增高,且与TBIL呈显著正相关(γs=0.549,P=0.000),但与γ-GT的相关性没有统计学意义(γs=0.291,P=0.062)。结论 TNFSF9可能参与了PBC的发病机制,可能是一个潜在的治疗靶点。Objective To investigate the concentration of TNFSF9 in sera of primary biliary cirrhosis (PBC) patients and its clinical significance.Methods The serum TNFSF9 level was measured in PBC patients and healthy controls by ELISA.Its correlation with TBIL and ?? GT in PBC patients were analyzed.Results The serum concentration of TNFSF9 was higher in PBC patients (1102.45 ±294.48 ng/mL) than that in healthy controls (123.67 ±62.60 ng/mL) .Serum TNFSF9 concentration was positively correlated with TBIL (γs=0.549,P=0.000) ,but not with γ-GT (γs=0.291,P=0.062) .Conclusion TNFSF9 may be involved in the pathogenesis of PBC,and may be a potential therapy target for such a disease.

关 键 词：原发性胆汁性肝硬化 表达 临床意义 CLINICAL SIGNIFICANCE 患者血清 酶联免疫吸附试验 统计学意义 健康人血清 治疗靶点 浓度变化 发病机制 正相关 对照组 ELISA 配对 结果 检测 关系 分析 方法 

分 类 号：R82[医药卫生—临床医学]